Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma-Aldrich® Partners with Scripps Research Institute

Published: Friday, July 19, 2013
Last Updated: Friday, July 19, 2013
Bookmark and Share
The agreement marks first partnership of its kind between a research institution and reagents company.

Sigma-Aldrich announce a partnership with The Scripps Research Institute (TSRI) to fund research and provide immediate, day-of-publication access to TSRI researchers' discoveries for the synthesis and analysis of potential drugs. The partnership promises to eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery.

The partnership includes six TSRI research labs led by Professors Phil Baran, Jin-Quan Yu, Benjamin Cravatt, Carlos Barbas, Phillip Dawson, and Nobel Laureate K. Barry Sharpless. TSRI will receive funds to be used to expand capacity for basic research.

TSRI approached Sigma-Aldrich to eliminate the delay between the invention of novel reagents and reliable, widespread access to those reagents for the translational research community. "The hurdles from bench to clinic, what the NIH calls the 'valley of death', are proving difficult to surmount, leaving numbers of potential therapeutic ideas trapped inside university doors. To clear these hurdles, it's critical to open a myriad of novel technologies, such as these from TSRI, to the whole translational research community," said Amanda Halford, Vice President, Academic Research at Sigma-Aldrich.

"This is the third major deal in our new targeted partnership strategy, following recent agreements with Janssen Pharmaceuticals and Bristol-Myers Squibb," said Scott Forrest, Vice President of Business Development at TSRI. "These multi-lab, multi-year alliances fund research and infrastructure in areas of mutual interest, creating a win-win situation for moving innovations into the marketplace. We are pleased to partner with the world's leading reagent company to accelerate the commercialization of new research tools for the scientific community."

Sigma-Aldrich and TSRI will partner to fund development of novel reagents from the six TSRI labs, which Sigma-Aldrich will commercialize exclusively via a master licensing agreement. This will allow unfettered access to new reagents by chemists and also scientists who do not have a background in chemical synthesis, which in the past limited their ability to implement novel reagents in their research.

Last year, TSRI and Sigma-Aldrich established a partnership to produce in bulk a toolkit of ten novel zinc-based salts discovered in the Baran lab, including the Baran difluoromethylation reagent that several large pharmaceutical companies immediately adopted for optimizing lead compounds.

"The partnership with TSRI will enable us to expand our portfolio through new innovations and product development," said Eric Green, Executive Vice President and President, Research at Sigma-Aldrich.  "We believe this partnership reinforces our strategy of broadening our research portfolio of innovative products and tools used by the translational research community."

Publications of new reagents developed in these six TSRI labs will include a Sigma-Aldrich product number for simple reference.

While a number of collaborative partnerships have emerged between academic institutions and pharmaceutical companies, this is the first partnership of its kind between a research institute and a reagents company.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Plasticell Signs Technology Agreement with Sigma-Aldrich
Collaboration to produce novel turnkey solution for stem cell research.
Tuesday, November 30, 2010
Sigma-Aldrich Licenses from NeuroSurvival Technologies a Marker for Molecular Imaging of Apoptosis in Vivo
The marker, Apo-TRACE™, offers a breakthrough in advancing apoptosis-related research in a range of fields in biology and medicine.
Wednesday, February 27, 2008
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!